<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04736381</url>
  </required_header>
  <id_info>
    <org_study_id>C 19-53</org_study_id>
    <nct_id>NCT04736381</nct_id>
  </id_info>
  <brief_title>Impact of the Microbiota on the Likelihood of Renal Graft Rejection</brief_title>
  <acronym>MERRLIN</acronym>
  <official_title>Impact of the Microbiota on the Likelihood of Renal Graft Rejection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut National de la Santé Et de la Recherche Médicale, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Identification of a bacterial signature in the blood or stool that may be associated with&#xD;
      acute rejection in patients treated with Nulojix during their first year of transplant.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Gut microbiota as well as the signature of the 16S plasma bacterial DNA and bacterial&#xD;
      metabolites of patients on the date of transplantation and during the first year after&#xD;
      transplantation will be analyzed. The phenotype of the patients' T lymphocytes will be&#xD;
      analyzed at the same time. These data will be correlated with the occurrence of acute cell&#xD;
      rejection during the first year of transplantation&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 14, 2021</start_date>
  <completion_date type="Anticipated">September 27, 2024</completion_date>
  <primary_completion_date type="Anticipated">September 29, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Acute rejection occurence</measure>
    <time_frame>1 year or rejection</time_frame>
    <description>Occurence of cellular rejection according to the BANFF 2017</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Gut and circulating microbiota</measure>
    <time_frame>1 year or rejection</time_frame>
    <description>16S DNA sequencing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lymphocyte phenotype</measure>
    <time_frame>1 year or rejection</time_frame>
    <description>CD3+CD4+CD57+PD1-, CD3+CD8+CD28low, CD3+CD8+CD45RA phenotype</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glomerular filtration rate</measure>
    <time_frame>1 year or rejection</time_frame>
    <description>CDK-EPI creatinine equation</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Kidney Transplant Rejection</condition>
  <arm_group>
    <arm_group_label>Kidney transplanted patients treated with Nulojix</arm_group_label>
    <description>Patients treated with Simulect as induction, and with Nulojix®, mycophenolic acid and steroids as maintenance therapy during the first year of kidney transplant.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Belatacept Injection [Nulojix]</intervention_name>
    <description>Drugs administrated are part of the usual care</description>
    <arm_group_label>Kidney transplanted patients treated with Nulojix</arm_group_label>
    <other_name>Simulect</other_name>
    <other_name>Mycophenolate mofetil</other_name>
    <other_name>Steroid</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood Stool&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        70 patients treated with Simulect as induction, and with Nulojix®, mycophenolic acid and&#xD;
        steroids as maintenance therapy during the first year of kidney transplant.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients called for a kidney transplant&#xD;
&#xD;
          -  Induction therapy with Simulect, maintenance therapy with Nulojix, mycophenolate acid&#xD;
             and steroids&#xD;
&#xD;
          -  Patient having signed the informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Multiple grafts combined or sequential&#xD;
&#xD;
          -  Induction therapy with polyclonal antibodies&#xD;
&#xD;
          -  HIV or active viral infection such as hepatitis B or C&#xD;
&#xD;
          -  Active bacterial infection&#xD;
&#xD;
          -  Pregnancy or breastfeeding at time of inclusion&#xD;
&#xD;
          -  Patient unable to express their consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antoine Durrbach, MD-PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut National de la Santé Et de la Recherche Médicale, France</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Antoine Durrbach, MD-PhD</last_name>
    <phone>+33614112981</phone>
    <email>antoine.durrbach@inserm.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>florence Herr, PhD</last_name>
    <phone>+33663680985</phone>
    <email>florence.herr@inserm.fr</email>
  </overall_contact_backup>
  <reference>
    <citation>Vincenti F, Blancho G, Durrbach A, Friend P, Grinyo J, Halloran PF, Klempnauer J, Lang P, Larsen CP, Mühlbacher F, Nashan B, Soulillou JP, Vanrenterghem Y, Wekerle T, Agarwal M, Gujrathi S, Shen J, Shi R, Townsend R, Charpentier B. Five-year safety and efficacy of belatacept in renal transplantation. J Am Soc Nephrol. 2010 Sep;21(9):1587-96. doi: 10.1681/ASN.2009111109. Epub 2010 Jul 15.</citation>
    <PMID>20634298</PMID>
  </reference>
  <reference>
    <citation>Durrbach A, Pestana JM, Pearson T, Vincenti F, Garcia VD, Campistol J, Rial Mdel C, Florman S, Block A, Di Russo G, Xing J, Garg P, Grinyó J. A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study). Am J Transplant. 2010 Mar;10(3):547-57. doi: 10.1111/j.1600-6143.2010.03016.x.</citation>
    <PMID>20415898</PMID>
  </reference>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 29, 2021</study_first_submitted>
  <study_first_submitted_qc>January 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 3, 2021</study_first_posted>
  <last_update_submitted>January 29, 2021</last_update_submitted>
  <last_update_submitted_qc>January 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Microbiota</keyword>
  <keyword>Belatacept</keyword>
  <keyword>Second signal inhibitor</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Abatacept</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

